Study of Pz-cel for patients with wound healing needs
Part of Genetic & congenital, Skin clinical trials.
This trial tests a skin cell treatment called pz-cel (made from your own cells) for people with a severe skin condition called dystrophic epidermolysis bullosa (DEB). It aims to help heal wounds by applying specially grown skin sheets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child have dystrophic epidermolysis bullosa (DEB) and wounds that need treatment.
- You are expected to receive pz-cel as part of your care (commercial or special access).
- You can follow the study plan and protect the treated skin areas.
- You do not have active infections (like HIV, hepatitis B or C) or skin cancer in the treatment area.
- You are not allergic to the antibiotics vancomycin or amikacin.
- If you could become pregnant, you agree to use birth control and discuss plans with your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This study is a safety follow-up for people who already completed the SD-007 trial. It gives everyone SD-101, an experimental treatment for epidermolysis bullosa, to see how well it works over a longer period.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.